mProX™ Human CCR3 Stable Cell Line

Tang HY, et al. "[Identification and preliminary validation of potential biomarkers in the ." Zhonghua yi xue za zhi, 2023.
The study aimed to compare the transcriptomes of peripheral blood mononuclear cells (PBMC) in individuals with atopic dermatitis (AD) and healthy controls, and to identify potential biomarkers for AD. Blood samples were collected from 9 AD patients and 10 healthy controls between January 2021 to May 2022. RNA-sequencing (RNA-seq) was used to analyze the PBMC transcriptomes and differentially expressed genes (DEGs). Gene ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) and protein-protein interaction (PPI) network analysis were performed to identify potential biomarkers. Results showed that AD patients (mean age: 26.50 years) had a significantly earlier onset of disease (mean course: 15 years) compared to healthy controls (mean age: 37.00 years). PBMC samples from AD patients showed 1,044 DEGs, with a higher expression of 668 genes and a lower expression of 376 genes compared to healthy controls. Additionally, differential variable splicing (AS) indicated that mutually exclusive exons (46.74%) and skipped exon (31.01%) were the most common AS patterns. GO and KEGG analyses revealed that DEGs in AD were involved in the inflammatory response, cytokine interaction, and signaling pathways. Based on comprehensive enrichment analysis and PPI analysis, eight candidate genes (CCL4, CCR3, CXCR5, NFKBIA, CXCL1, IL-1B, CCL20, LY96) were identified and confirmed by quantitative real-time PCR (qRT-PCR). These genes may serve as potential biomarkers and play a role in the pathogenesis of AD.
Pubmed: 37813654   DOI: 10.3760/cma.j.cn112137-20230128-00128

Chai H, et al. "Profiling CCR3 target pathways for discovering novel antagonists from natural ." Chemico-biological interactions, 2023.
The CC chemokine receptor 3 (CCR3) is a crucial factor in the development of atopic dermatitis (AD) and other related allergic diseases. Its activation leads to the recruitment of eosinophils, causing inflammatory responses by releasing inflammatory mediators. However, no known CCR3 antagonists have shown significant efficacy in clinical trials. In this study, researchers aimed to identify new natural CCR3 antagonists for potential drug development. To achieve this, they established a stably transfected CHO-K1-Galpha15-CCR3 cell line and verified receptor expression through various techniques. By utilizing a label-free cell phenotyping approach, they delineated the CCR3 target pathways and discovered that its activation triggers the Gq-PLC-Ca(2+) and MAPK-P38-ERK pathways. Through in vitro and in silico experiments, a novel CCR3 antagonist, emodin, was identified with an IC(50) value of 27.28,ÄØ+/-,ÄØ1.71,ÄØmuM out of 266 compounds from 15 traditional Chinese medicines commonly used for skin diseases. Molecular docking revealed the binding mode of emodin on CCR3. These findings not only present a new method for CCR3 antagonist screening and pathway detection but also highlight the potential of emodin as a future drug for allergic diseases.
Pubmed: 37788752   DOI: 10.1016/j.cbi.2023.110732